Atlas Venture
http://www.atlasventure.com/Atlas Venture is a venture capital firm that invests in early stage technology and life sciences businesses. Since the firm’s founding in 1980, the firm has helped build over three hundred companies. Since 1995, forty seven of its investments have been acquired and more than forty have gone public, with an aggregate market capitalization of over $20 billion.
View Older Stories View More Recent Stories
-
Surface Oncology Announces Collaboration with Dr. John Stagg, a World-Leader in the Adenosine Pathway
-
Surface Oncology Appoints Robert Ross, MD as Chief Medical Officer
-
Synlogic Appoints COO and Head of Corporate Development
-
ProfNet Experts Available on Antibiotic Resistance, Seasonal Affective Disorder, More
-
Founder and CEO of Replimune Limited Honored with the IPO Education Foundation's 43rd Annual Inventor of the Year Award
-
Surface Oncology CD47 Program Demonstrates Promising Anti-Tumor Activity in Hematological Disease Models
-
Magenta Therapeutics Announces $48.5M Series A Financing to Transform Stem Cell Transplant for Immune and Blood Diseases
-
Synlogic Secures Patent on Proprietary Synthetic Probiotic Bacteria for the Treatment of Hyperammonemia
-
SaltDNA Adds Desktop Application to Its Secure Mobile Communication Solution for the Enterprise
-
Signal Genetics (SGNL) to Merge with Miragen Therapeutics
-
miRagen Therapeutics and Signal Genetics Sign Merger Agreement
-
IFM Therapeutics Establishes German Subsidiary and Research Site
-
Global drug development executives converge on Boston for BioPharm America™ 2016
-
Rodin Expands Leadership Team and Advisory Boards to Advance Novel, Selective HDAC Inhibitors Towards the Clinic
-
ZappRx Hires Biopharmaceutical Industry Leader as Chief Operating Officer
-
Delinia Announces $35 Million Series A Financing to Advance Novel Therapeutics Targeting Regulatory T Cells for Autoimmune Diseases
-
Synlogic Expands Leadership Team to Support Rapid Advancement of the First Synthetic Biotic Towards the Clinic
-
Armored Cloud Announces Partnership with SaltDNA for Enterprise Encrypted Mobile Communication
-
IFM Therapeutics Appoints Leading Oncology, Immunology, and Chemistry Experts to Founding Scientific Advisory Board
-
Synlogic Proprietary Synthetic Biotic Receives FDA Orphan Drug Designation
-
AVROBIO, Inc. Announces $25 Million Series A Financing to Advance Novel, Clinical-Stage Gene Therapies for Rare Diseases and Cancer
-
SaltDNA and Copperhead Partner to Provide End-to-End Encrypted Mobile Communications with Full Device Security
-
Quartet Medicine Appoints Gerhard Koenig, Ph.D., as Chief Executive Officer
-
Key life science industry thought leaders and new one-day programs elevate offerings at BioPharm America™ 2016
-
World Renowned Entrepreneur Laura Morse Joins PixarBio’s Board of Directors as PixarBio Prepares for SEC Compliance
-
IFM Therapeutics Raises $27 Million Series A Financing Led by Atlas Venture and Abingworth
-
Form 4 Intellia Therapeutics, For: May 11 Filed by: Atlas Venture Fund IX, L.P.
-
Form 3 Intellia Therapeutics, For: May 05 Filed by: Atlas Venture Fund IX, L.P.
-
Ivan Baker Joins Inmoji as Vice President, Business Development
-
Synlogic Appoints an Industry Leader Nick Leschly to Its Board of Directors
-
SaltDNA Introduces First Encrypted Conference Calling Feature for Secure Mobile Communications
-
Inmoji Secures $5 Million in Series A Funding to Fuel Growth and Innovation in Branded Interactive Emojis for Mobile Messaging
-
Evotec Achieves Milestone in Collaboration with Padlock Therapeutics
-
LTG Exam Platform Secures $5.3 Million in Series A Funding to Fuel Strategic Plan for Rapid Expansion
-
AVROBIO Inc. Launches to Develop Novel, Clinical-Stage Cell and Gene Therapies Targeting Immuno-Oncology and Rare Diseases
-
Synlogic Secures $40 Million in Series B Financing
-
Crowdynews Adds New Board Members And Creates Advisory Board
-
Form SC 13G/A Vitae Pharmaceuticals, Filed by: ATLAS VENTURE FUND VI LP
-
Form SC 13G/A ZAFGEN, INC. Filed by: Atlas Venture Fund VII L P
-
Form SC 13G/A Egalet Corp Filed by: Atlas Venture Fund VII L P
-
Machine Learning Company DataRobot Accelerates Growth with $33 Million in New Funding
-
Synlogic Announces First Industry Collaboration to Develop a New Class of Medicines Designed to Power the Microbiome
-
Spero Therapeutics Announces $30 Million Series B Preferred Financing
-
Lexumo Funded to Secure IoT and Embedded Devices, Critical Infrastructure, and Enterprise Applications from Widespread Open Source Vulnerabilities
-
Vito Palombella, PhD Joins Surface Oncology as Chief Scientific Officer
-
JenaValve Technology Appoints Pieter Van den Steen As Chief Commercial Officer, General Manager
-
Upsher-Smith And Saniona Sign Collaboration Agreement For Development Of Novel Therapeutics For Neurological Disorders
-
Joshua Resnick, MD Joins SV Life Sciences as Partner
-
Surface Oncology Announces Global Strategic Collaboration to Advance Next-Generation Immunotherapies
-
JenaValve Technology Appoints Janet M. Fauls As Vice President Of Regulatory Affairs

